Rama Krishna Narla

2.2k total citations
51 papers, 1.3k citations indexed

About

Rama Krishna Narla is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Rama Krishna Narla has authored 51 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 17 papers in Oncology and 13 papers in Organic Chemistry. Recurrent topics in Rama Krishna Narla's work include Vanadium and Halogenation Chemistry (7 papers), Protein Degradation and Inhibitors (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Rama Krishna Narla is often cited by papers focused on Vanadium and Halogenation Chemistry (7 papers), Protein Degradation and Inhibitors (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Rama Krishna Narla collaborates with scholars based in United States, Switzerland and Germany. Rama Krishna Narla's co-authors include Fatih M. Uckun, Phalguni Ghosh, Christopher S. Navara, E. Sudbeck, Osmond J. D’Cruz, Yanhong Dong, Xingping Liu, Sutapa Ghosh, Mao Chen and Sandeep Mahajan and has published in prestigious journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Rama Krishna Narla

50 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rama Krishna Narla United States 20 572 534 295 283 155 51 1.3k
Sara M. Schmitt United States 14 1.0k 1.8× 834 1.6× 128 0.4× 451 1.6× 122 0.8× 20 1.9k
Brian E. Schultz United States 18 881 1.5× 379 0.7× 237 0.8× 268 0.9× 175 1.1× 33 1.8k
Paolo Lunghi Italy 27 1.1k 1.9× 1.0k 1.9× 344 1.2× 653 2.3× 139 0.9× 45 2.2k
Francis L. McCabe United States 18 1.0k 1.8× 1.0k 1.9× 181 0.6× 623 2.2× 314 2.0× 22 2.0k
Christopher J. O’Donnell United States 27 835 1.5× 483 0.9× 106 0.4× 799 2.8× 73 0.5× 54 2.1k
Jimin Shao China 24 1.2k 2.1× 716 1.3× 331 1.1× 140 0.5× 168 1.1× 59 1.9k
Brigitte Kircher Austria 22 294 0.5× 619 1.2× 144 0.5× 592 2.1× 245 1.6× 63 1.4k
Siavosh Mahboobi Germany 26 1.0k 1.8× 369 0.7× 85 0.3× 858 3.0× 61 0.4× 76 1.8k
Jinxin Che China 19 484 0.8× 199 0.4× 158 0.5× 142 0.5× 84 0.5× 80 966
Matthew Ho United States 14 643 1.1× 322 0.6× 60 0.2× 541 1.9× 139 0.9× 39 1.5k

Countries citing papers authored by Rama Krishna Narla

Since Specialization
Citations

This map shows the geographic impact of Rama Krishna Narla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rama Krishna Narla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rama Krishna Narla more than expected).

Fields of papers citing papers by Rama Krishna Narla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rama Krishna Narla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rama Krishna Narla. The network helps show where Rama Krishna Narla may publish in the future.

Co-authorship network of co-authors of Rama Krishna Narla

This figure shows the co-authorship network connecting the top 25 collaborators of Rama Krishna Narla. A scholar is included among the top collaborators of Rama Krishna Narla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rama Krishna Narla. Rama Krishna Narla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carrancio, Soraya, Lynda Groocock, Ryan Galasso, et al.. (2021). CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma. Blood. 138(Supplement 1). 1200–1200. 12 indexed citations
2.
Lopez‐Girona, Antonia, Lynda Groocock, Zhongying Mo, et al.. (2021). CC‐99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). Hematological Oncology. 39(S2). 4 indexed citations
3.
Nakayama, Yumi, Hsiling Chiu, Rama Krishna Narla, et al.. (2021). Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing. Blood. 138(Supplement 1). 718–718.
4.
Narla, Rama Krishna, Hardik Modi, Daniel E. Bauer, et al.. (2021). Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunology Immunotherapy. 71(2). 473–489. 29 indexed citations
5.
Zhu, Dan, Shuichan Xu, Gordafaried Deyanat‐Yazdi, et al.. (2018). Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint. Molecular Cancer Therapeutics. 17(8). 1727–1738. 28 indexed citations
6.
Narla, Rama Krishna, Hardik Modi, Lilly Wong, et al.. (2017). Abstract 4694: The humanized anti-CD47 monclonal antibody, CC-90002, has antitumor activity in vitro and in vivo. Cancer Research. 77(13_Supplement). 4694–4694. 13 indexed citations
7.
Narla, Rama Krishna, Jason D. Katz, Julius Apuy, et al.. (2013). Abstract A165: Antitumor activity of mTOR kinase inhibitor CC-223 in a mouse model of prostate cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). A165–A165. 1 indexed citations
8.
9.
Mortensen, Deborah S., John Sapienza, Brandon Whitefield, et al.. (2013). Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorganic & Medicinal Chemistry Letters. 23(6). 1588–1591. 20 indexed citations
10.
Mortensen, Deborah S., Kimberly E. Fultz, Matthew Hickman, et al.. (2012). 337 The Discovery and Preclinical Characterization of CC-223, a Novel mTOR Kinase Inhibitor Under Clinical Investigation. European Journal of Cancer. 48. 103–103. 2 indexed citations
11.
Uckun, Fatih M., Osmond J. D’Cruz, Xingping Liu, & Rama Krishna Narla. (2003). Phenylarsonic Acid Compounds with Broad‐Spectrum and Potent Cytotoxic Activity Against Human Cancer Cells.. ChemInform. 34(38). 1 indexed citations
12.
Narla, Rama Krishna, et al.. (2001). Chemosensitivity of TEL-AML1 Fusion Transcript Positive Acute Lymphoblastic Leukemia Cells. Leukemia & lymphoma. 41(5-6). 615–623. 15 indexed citations
13.
Perrey, David A., et al.. (2000). The S-alkyl chain length as a determinant of the anti-leukemic activity of cysteine chloromethyl ketone compounds. Bioorganic & Medicinal Chemistry Letters. 10(6). 551–552. 8 indexed citations
14.
Uckun, Fatih M., et al.. (2000). A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorganic & Medicinal Chemistry Letters. 10(10). 1015–1018. 10 indexed citations
15.
Dong, Yanhong, T.K. Venkatachalam, Rama Krishna Narla, et al.. (2000). Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorganic & Medicinal Chemistry Letters. 10(1). 87–90. 42 indexed citations
16.
Perrey, David A., Rama Krishna Narla, & Fatih M. Uckun. (2000). Cysteine chloromethyl and diazomethyl ketone derivatives with potent anti-leukemic activity. Bioorganic & Medicinal Chemistry Letters. 10(6). 547–549. 9 indexed citations
17.
Narla, Rama Krishna, et al.. (1999). A QUANTITATIVE HPLC DETECTION METHOD FOR WHI-P154 [4-(3′-BROMO-4′-HYDROXYLPHENYL)-AMINO-6,7-DIMETHOXYQUINAZOLINE]. Journal of Liquid Chromatography & Related Technologies. 22(11). 1771–1783. 4 indexed citations
18.
Aubrecht, Jiri, et al.. (1999). Molecular Genotoxicity Profiles of Apoptosis-Inducing Vanadocene Complexes. Toxicology and Applied Pharmacology. 154(3). 228–235. 59 indexed citations
19.
Uckun, Fatih M., Rama Krishna Narla, Jun Xu, et al.. (1998). Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells.. PubMed. 4(4). 901–12. 64 indexed citations
20.
Ghosh, Sutapa, Yaguo Zheng, Jun Xu, et al.. (1998). Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells.. PubMed. 4(11). 2657–68. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara M. Schmitt Breakdown of academic impact, for papers by Brian E. Schultz Breakdown of academic impact, for papers by Paolo Lunghi Breakdown of academic impact, for papers by Francis L. McCabe Breakdown of academic impact, for papers by Christopher J. O’Donnell Breakdown of academic impact, for papers by Jimin Shao Breakdown of academic impact, for papers by Brigitte Kircher Breakdown of academic impact, for papers by Siavosh Mahboobi Breakdown of academic impact, for papers by Jinxin Che Breakdown of academic impact, for papers by Matthew Ho
Rankless by CCL
2026